The p-values for interaction were less than 0.05 in both the HER2 subgroup and T3-4 subgroup, indicating that antibiotic administration might change the outcome in HER2-positive BC patients and those whose primary tumor was larger than 5 cm. The gene discussed is ERBB2; the disease is neoplasm.